KarXT clinical trials
KarXT is named as an intervention in 27 current clinical trials in our USA, Poland, Japan, Spain, France, India, Italy, UK, Germany, China, Canada, Australia, South Korea, Israel, Brazil, Czechia, Portugal, Mexico, Belgium, Turkey, Netherlands, Taiwan, Sweden, Denmark and Switzerland registers. 24 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Bristol-Myers Squibb (19). The most-studied condition is Schizophrenia. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Patient leaflets for KarXT
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of KarXT
27 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
KarXT in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing KarXT. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 3 Double-blind, Placebo-controlled Randomized Withdrawal Maintenance Trial of KarXT Treatment in Participants with Schizophrenia
2025-523664-20-00 · CTIS ↗ · Mental Disorders
|
Phase 3 | Authorised | Bristol-Myers Squibb Services Unlimited Company | Romania, Bulgaria, Poland + 2 more |
|
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals with Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
2025-521845-26-00 · CTIS ↗ · Mental Disorders
|
Phase 3 | Ongoing | Bristol-Myers Squibb Services Unlimited Company | Romania, Poland, France + 3 more |
Conditions studied with KarXT
14 conditionsAll 14 conditions
| Condition (as registered) | Trials |
|---|---|
| Schizophrenia | 8 |
| Alzheimer Disease | 4 |
| Alzheimer's Disease | 3 |
| Psychosis Associated With Alzheimer's Disease | 3 |
| Healthy Volunteers | 3 |
| Irritability Associated With Autism Spectrum Disorder | 2 |
| Agitation | 1 |
| Psychosis | 1 |
| Bipolar Disorder Type I With Mania or Mania With Mixed Features | 1 |
| Mania | 1 |
| Bipolar Disorder | 1 |
| Autism-Related Irritability | 1 |
| Bipolar Disorder Type I With Mania | 1 |
| Bipolar-I Disorder With Mania or Mania With Mixed Features | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Bristol-Myers Squibb | 19 |
| Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 8 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about KarXT trials
How many clinical trials are testing KarXT?
27 current trials in our USA, Poland, Japan, Spain, France, India, Italy, UK, Germany, China, Canada, Australia, South Korea, Israel, Brazil, Czechia, Portugal, Mexico, Belgium, Turkey, Netherlands, Taiwan, Sweden, Denmark and Switzerland registers name KarXT (also registered as BMS-986510) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are KarXT trials recruiting patients?
Yes. 24 of the 27 trials are recruiting: 22 with sites in USA, 12 with sites in Poland, 12 with sites in Japan, 11 with sites in Spain, 10 with sites in France, 10 with sites in India, 10 with sites in Italy, 8 with sites in UK, 7 with sites in Germany, 8 with sites in China, 7 with sites in Canada, 6 with sites in Australia, 7 with sites in South Korea, 7 with sites in Israel, 6 with sites in Brazil, 6 with sites in Czechia, 5 with sites in Portugal, 4 with sites in Mexico, 3 with sites in Belgium, 3 with sites in Turkey, 2 with sites in Netherlands, 2 with sites in Taiwan, 2 with sites in Sweden, 2 with sites in Denmark and 1 with sites in Switzerland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors KarXT clinical trials?
Bristol-Myers Squibb (19) and Karuna Therapeutics, Inc., a Bristol Myers Squibb company (8). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how KarXT works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how KarXT works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists KarXT (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.